Published in J Virol on April 01, 1995
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Construction of adenovirus vectors through Cre-lox recombination. J Virol (1997) 6.72
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol (1996) 6.43
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol (1998) 3.14
Replication-defective vector based on a chimpanzee adenovirus. J Virol (2001) 2.86
MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics (2010) 2.80
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol (2004) 2.58
Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol (1996) 2.46
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 2.33
Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med (1997) 2.12
Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 2.12
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol (1998) 2.06
Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol (1995) 2.05
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol (1996) 1.89
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 1.86
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol (1997) 1.78
Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A (1998) 1.76
An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A (1998) 1.76
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol (1998) 1.75
Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol (1998) 1.72
Disruption of the c/ebp alpha gene in adult mouse liver. Mol Cell Biol (1997) 1.72
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A (1996) 1.72
Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol (1996) 1.70
Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol (1996) 1.61
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol (1999) 1.61
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest (1997) 1.57
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest (1999) 1.56
Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol (1997) 1.56
Positron emission tomography imaging of conditional gene activation in the heart. J Mol Cell Cardiol (2007) 1.56
Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol (1996) 1.56
"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol (2001) 1.53
Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol (1996) 1.50
Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation (2002) 1.50
TNF-alpha -dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci U S A (2001) 1.49
Influence of cell polarity on retrovirus-mediated gene transfer to differentiated human airway epithelia. J Virol (1998) 1.46
Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol (1997) 1.46
In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol (1998) 1.45
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol (1996) 1.43
Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol (2000) 1.42
A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol (1997) 1.42
Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 1.42
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 1.39
Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol (1998) 1.38
Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci U S A (1997) 1.37
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther (2007) 1.36
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35
Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest (2005) 1.35
Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A (1997) 1.35
Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol (2002) 1.34
Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther (2006) 1.34
Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol (2006) 1.32
Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol (1998) 1.28
Role for the adenovirus IVa2 protein in packaging of viral DNA. J Virol (2001) 1.28
Augmentation of lung liquid clearance via adenovirus-mediated transfer of a Na,K-ATPase beta1 subunit gene. J Clin Invest (1998) 1.27
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A (1997) 1.26
Circumvention of immunity to the adenovirus major coat protein hexon. J Virol (1998) 1.26
Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci U S A (1996) 1.25
The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem (2009) 1.25
Development of nonhuman adenoviruses as vaccine vectors. Vaccine (2005) 1.25
Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest (1995) 1.23
Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One (2011) 1.22
Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol (2002) 1.20
Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol (2005) 1.19
Adenovirus 3 penton dodecahedron exhibits structural changes of the base on fibre binding. EMBO J (1996) 1.18
Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression. J Virol (2000) 1.18
Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol (1997) 1.17
Factors governing the assembly of cationic phospholipid-DNA complexes. Biophys J (2000) 1.17
Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol (2000) 1.17
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A (1998) 1.17
Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol (1999) 1.17
Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther (2011) 1.16
Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest (1997) 1.15
Silk-elastinlike recombinant polymers for gene therapy of head and neck cancer: from molecular definition to controlled gene expression. J Control Release (2009) 1.15
Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol (1999) 1.15
Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol (2006) 1.14
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol (2004) 1.11
Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol (2006) 1.10
Inhibition of tumor necrosis factor alpha-induced NF-kappa B activation by the adenovirus E3-10.4/14.5K complex. J Virol (2002) 1.10
Extended transgene expression from a nonintegrating adenoviral vector containing retroviral elements. Mol Ther (2008) 1.10
Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest (2009) 1.09
Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol (2006) 1.09
Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J Virol (2001) 1.09
Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther (2012) 1.08
Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest (1995) 1.08
Advances in cell and gene-based therapies for cystic fibrosis lung disease. Mol Ther (2012) 1.08
T cells cause acute immunopathology and are required for long-term survival in mouse adenovirus type 1-induced encephalomyelitis. J Virol (2003) 1.07
Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther (2011) 1.07
Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol (2008) 1.07
Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol (1998) 1.06
Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci (2010) 1.05
Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins. J Virol (1998) 1.04
Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mol Med (1997) 1.04
Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J (2008) 1.03
RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell (1992) 17.50
Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature (1990) 8.57
Lymphocyte responses and cytokines. Cell (1994) 8.35
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science (1991) 7.25
MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell (1994) 6.92
In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell (1992) 5.85
Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1A-like activity. Mol Cell Biol (1984) 4.76
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 4.65
Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet (1992) 4.12
Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A (1994) 4.06
Cystic fibrosis: molecular biology and therapeutic implications. Science (1992) 3.72
Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet (1994) 3.56
Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A (1994) 3.38
Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet (1992) 2.79
Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet (1993) 2.67
Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther (1993) 2.48
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet (1993) 2.31
Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). J Virol (1993) 2.20
NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A. J Virol (1992) 2.10
Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice. J Exp Med (1993) 2.07
Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology (1994) 2.04
Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther (1994) 1.70
Expression of the cystic fibrosis gene in adult human lung. J Clin Invest (1994) 1.70
An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci U S A (1993) 1.57
Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice. J Immunol (1991) 1.29
The murine cellular immune response to adenovirus type 5. Immunol Cell Biol (1989) 1.10
Cystic fibrosis. Vehicles for gene therapy. Nature (1993) 1.04
The "beta-like-globin" gene domain in human erythroid cells. Proc Natl Acad Sci U S A (1985) 8.35
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 5.99
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol (1996) 5.94
Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey. Tob Control (2006) 5.63
Membrane compartmentation is required for efficient T cell activation. Immunity (1998) 5.00
Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med (1997) 4.87
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 4.65
Gene therapy vectors based on adeno-associated virus type 1. J Virol (1999) 4.63
Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell (2001) 4.61
Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res (1998) 4.39
Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A (1992) 4.38
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet (1994) 4.33
Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet (1992) 4.12
Studies on alcaptonuria: 2. Investigations on a case of human alcaptonuria. Biochem J (1947) 4.03
Higher cigarette prices influence cigarette purchase patterns. Tob Control (2005) 3.98
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A (1997) 3.84
The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A (1998) 3.83
Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem (2000) 3.74
Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell (1990) 3.70
Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet (1994) 3.56
Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest (1998) 3.51
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res (1999) 3.48
Conditional ablation of beta1 integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination. J Cell Biol (2000) 3.38
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A (1994) 3.38
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol (1998) 3.14
Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res (1997) 3.09
China's forest policy for the 21st century. Science (2000) 3.04
Natural variation in light sensitivity of Arabidopsis. Nat Genet (2001) 2.97
Screening for refractive errors at age 1 year: a pilot study. Br J Ophthalmol (1979) 2.94
Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet (2001) 2.88
Replication-defective vector based on a chimpanzee adenovirus. J Virol (2001) 2.86
Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther (2001) 2.83
Screening for visual defects in preschoolchildren. Br J Ophthalmol (1986) 2.82
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. J Virol (1998) 2.71
Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem (2000) 2.70
Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther (2001) 2.69
Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet (1993) 2.67
Biomechanical energy harvesting: generating electricity during walking with minimal user effort. Science (2008) 2.66
A first attempt to prevent amblyopia and squint by spectacle correction of abnormal refractions from age 1 year. Br J Ophthalmol (1985) 2.65
Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res (2011) 2.64
Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity (1995) 2.63
Gene therapy: adenovirus vectors. Curr Opin Genet Dev (1993) 2.61
A possible nucleotide-binding domain in the tertiary fold of phosphoribosyltransferases. J Biol Chem (1983) 2.60
Complete genome sequence of the shrimp white spot bacilliform virus. J Virol (2001) 2.58
Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature (1994) 2.57
Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med (1995) 2.55
[Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam (1968) 2.54
Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther (2001) 2.53
A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet (1993) 2.53
Anteroapical stunning and left ventricular outflow tract obstruction. Mayo Clin Proc (2001) 2.48
Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther (1993) 2.48
The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A (1993) 2.48
Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol (2001) 2.46
Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Mol Pharmacol (1996) 2.45
Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther (1996) 2.43
The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem (2001) 2.37
Prediction of amblyopia and squint by means of refraction at age 1 year. Br J Ophthalmol (1986) 2.35
Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology (1996) 2.35
A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology (1996) 2.35
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 2.33
Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia (2011) 2.28
The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol (2000) 2.26
Epithelial injury induces keratocyte apoptosis: hypothesized role for the interleukin-1 system in the modulation of corneal tissue organization and wound healing. Exp Eye Res (1996) 2.25
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
Overlapping genomic sequences: a treasure trove of single-nucleotide polymorphisms. Genome Res (1998) 2.24
Single-nucleotide polymorphisms in the public domain: how useful are they? Nat Genet (2001) 2.24
CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science (1996) 2.21
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 2.19
A possible role for kinase-associated protein phosphatase in the Arabidopsis CLAVATA1 signaling pathway. Proc Natl Acad Sci U S A (1997) 2.19
The Silent Gallstone: A Ten to Twenty Year Follow-up Study of 112 Cases. Ann Surg (1948) 2.18
Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet (1999) 2.16
Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J Pharmacol (1996) 2.12
Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 2.12
Cell transplantation in liver-directed gene therapy. Cell Transplant (1994) 2.12
Function of the c-Myc oncogenic transcription factor. Exp Cell Res (1999) 2.11
Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science (1991) 2.11
Current surgical management of congenital diaphragmatic hernia: a report from the Congenital Diaphragmatic Hernia Study Group. J Pediatr Surg (1998) 2.09
Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med (1999) 2.07
Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther (1993) 2.07
Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol (1995) 2.05
Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology (1994) 2.04
Nucleotide sequence of 16-kilobase pairs of DNA 5' to the human epsilon-globin gene. J Biol Chem (1985) 2.02
Establishment of a small animal model for human Helicobacter pylori infection using germ-free mouse. Am J Gastroenterol (1994) 2.00
Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol (1999) 1.99
Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther (2000) 1.97
Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol (2001) 1.94
Adeno-associated virus as a vector for liver-directed gene therapy. J Virol (1998) 1.94
The innate immune system in cystic fibrosis lung disease. J Clin Invest (1999) 1.93
Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum Gene Ther (1992) 1.92
Benign small bowel tumor. Ann Surg (1975) 1.92
Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol (1997) 1.92